Aileron Therapeutics is a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides. Stapled Peptides are a breakthrough solution to address thousands of therapeutically important yet currently undruggable targets. Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and modulate protein-protein interactions, critical control points for most human diseases. Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases.

Stapled Peptide Targets

Stapled Peptides target intracellular control points that cannot be modulated by current therapeutics.

Watch Video

Stapled Peptides are produced by connecting two structurally optimized amino acids.

Watch Video

News

August 24, 2010
Roche and Aileron Enter Multi-target Alliance to Develop Stapled Peptide Drugs for Diseases across Multiple Therapeutic Areas
> Read Release

November 11, 2009
Aileron Therapeutics Collaborators Publish In Vivo Research in Nature Showing Stapled Peptides Achieve the First Direct Inhibition of the Notch1 Transcription Factor Oncogene
> Read Release

Recent Publications

Aileron Therapeutics Collaborators Publish In Vivo Research in Nature Showing Stapled Peptides Achieve the First Direct Inhibition of the Notch1 Transcription Factor Oncogene.
Read More

In an article published in Nature, Aileron’s proprietary Stapled Peptide drug candidate was shown to target a new and fundamental therapeutic mechanism.
Read More